Trials / Completed
CompletedNCT02057380
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | linsitinib | oral |
| DRUG | erlotinib | oral |
| DRUG | paclitaxel | Intravenous (IV) infusion |
| DRUG | Bortezomib | Subcutaneous or IV |
| DRUG | Dexamethasone | IV, Oral |
Timeline
- Start date
- 2014-04-16
- Primary completion
- 2016-10-14
- Completion
- 2016-12-21
- First posted
- 2014-02-07
- Last updated
- 2024-11-20
Locations
12 sites across 7 countries: United States, Brazil, Czechia, Germany, Poland, Singapore, Thailand
Source: ClinicalTrials.gov record NCT02057380. Inclusion in this directory is not an endorsement.